Purpose: A recent overview indicated that although routine patching is safer than routine primary closure after carotid endarterectomy (CEA), there is no systematic evidence that patch type influences outcome. However, most surgeons still believe that prosthetic patches are probably more thrombogenic than vein patches. This study tested the hypothesis that there was no difference in thrombogenicity between the different patch types. Methods: A total of 274 patients undergoing 276 CEAs were randomized to either Dacron-patch closure (n = 137) or vein-patch closure (n = 139). All patients with an accessible cranial window were monitored for 3 hours postoperatively with transcranial Doppler scanning (TCD). The number of emboli and rate of embolization were quantified with the requirement for selective dextran therapy to control high rates of postoperative embolization. All patients were assessed postoperatively and again at 30 days by a neurologist, and all patients underwent a duplex examination at 30 days. Results: The 30-day death/any stroke rate was 2.2% for patients in the Dacron-patch group and 3.6% for patients in the vein-patch group (P = .72). Patients in the Dacron-patch group had a higher incidence of postoperative emboli (median, 5; interquartile range, 0-10.5) than patients in the vein-patch group (median, 3; interquartile range, 1-17; P = .028). However, the incidence of detecting more than 50 emboli was virtually identical, and patch type had no effect on the incidence of high-rate, sustained embolization that required dextran therapy (5.3% for Dacron, 3.7% for vein). No patient had a carotid thrombosis at 30 days. Conclusion: Sustained, high-rate embolization, previously shown to be highly predictive of progression to carotid thrombosis, appears to be patient dependent, rather than related to patch type. (J Vasc Surg 2001;33:994-1000.)
A recent overview of the randomized trials of closure during carotid endarterectomy (CEA) suggested that a policy of routine patching was safer than a policy of routine primary closure because of a threefold reduction in perioperative thrombosis, early and late stroke, and late restenosis. 1 There is, however, no consensus on the optimal material to be used for patching. The principal advantages of vein include no cost, use of autogenous tissue, resistance to infection, and ease of handling. Disadvantages include harvest site complications and veinpatch rupture (which is reduced by harvesting the vein from the groin, but then the full length of vein is unavailable for future use). The advantages of prosthetic patches include immediate availability, no harvest-site complications, the avoidance of rupture, and preservation of the saphenous vein. Its principal disadvantage is infection. Although no significant difference in outcome between patch types was suggested by means of the meta-analysis, a perception remains among surgeons that prosthetic patches are probably more thrombogenic than vein patches.
Recent work from this unit has shown that as many as 70% of patients will have one or more emboli detected in the first 3 postoperative hours after CEA . 2 However, only about 5% of patients will have sustained, high-rate embolization, which has now been shown to be highly predictive of progression to carotid thrombosis and stroke. [3] [4] [5] [6] [7] When reexamined, these patients are found to have friable platelet thrombus adherent to the endarterectomy zone, usually with no evidence of any underlying technical error. 8 The current study was, therefore, specifically designed to quantify rates of postoperative embolization as an indicator of prothrombotic potential in a prospective, randomized trial of vein versus Dacron patches in patients undergoing CEA.
MATERIALS AND METHODS
The trial was approved by the Leicestershire Area Ethics Committee, and patients gave informed consent. A total of 294 patients undergoing CEA between December 1, 1997, and December 31, 1999, were considered for inclusion; 20 patients were subsequently excluded because of their refusal to give informed consent (n = 10), bilateral varicose vein surgery (n = 6), osteomyelitis (n = 1), severe claudication (n = 1), redo CEA (n = 1), and combined common carotid angioplasty plus CEA (n = 1). Therefore, 274 patients were randomized and underwent 276 CEAs. This paper details outcome, rate of embolization, and duplex findings at 30 days.
Randomization method. Three hundred computergenerated, random treatment methods (vein patch or Dacron patch) were consecutively numbered and sealed in opaque envelopes and allocated on a consecutive basis (immediately after induction of anesthesia), starting with envelope 1.
Carotid endarterectomy. Antiplatelet therapy was not stopped before surgery, and the patient's usual medication was administered on the morning of surgery. CEA was performed by a consultant vascular surgeon (n = 154) or supervised trainee (n = 122) with normotensive, normocarbic general anesthesia with loupe magnification, systemic administration of heparin (5000 units), routine shunting (Pruitt-Inahara, Ideas for Medicine, North Clearwater, Fla), and routine tacking sutures to the distal intimal step to prevent distal intimal dissection. Patients who were randomized to the vein-patch group had a segment of long saphenous vein harvested from the groin and anastomosed with 6:0 prolene suture (Ethicon Ltd, Somerville, NJ). Patients randomized to the Dacron-patch group had a Hemashield Finesse patch (Boston Scientific Ltd, St Albans, UK) inserted with 6:0 prolene suture (Ethicon). The vein patch was simply used at the width that it was when harvested (ie, the circumference of the vein); it was not trimmed to size. The Dacron patch was a standard 7 mm in width.
Blood flow velocity in the middle cerebral artery (MCA) was monitored throughout the procedure with a 2-MHz pulsed wave TCD ultrasound scanner, a SciMed PC2-64B, with a fixed-head probe system (Scimed UK, Bristol, UK) protected by a semicircular metal headguard with recording onto digital audiotape (DAT) for off-line analysis of emboli. 9,10 A 5-mm segment of the anastomosis (adjacent to the orifice of the external carotid artery) was left open. The shunt was removed, and the lumen was vented and irrigated with heparinized saline. Before final closure and restoration of flow, the lumen was inspected with a flexible hysteroscope (Olympus 1070-48; Olympus, Hamburg, Germany) to exclude residual luminal thrombus and intimal flaps. 10 After the procedure, the patient was transferred to the high dependency unit for further TCD monitoring. All emboli detected in the first 3 postoperative hours were recorded onto DAT tape and quantified off-line. Earlier studies from this unit have shown that postoperative emboli are exclusively particulate 9 and that 3 hours of monitoring is just as effective as 6 hours. 11, 12 Studies have shown that sustained postoperative embolization is highly predictive of progression to thrombosis and stroke 3, 7 and that this phase can be abolished with an incremental infusion of dextran. 11, 12 Accordingly, any patient who had 25 or more emboli in any 10-minute period or whose emboli distorted the MCA waveform (suggesting they were large) were given an incremental infusion of dextran 40. An initial bolus of 20 mL of 10% dextran 40 was administered, followed by an infusion at a rate that began at 20 mL/h. If the embolization rate failed to settle, the infusion rate was increased by 10 mL/h until embolization was controlled. The number of emboli and rate of embolization were quantified for every patient, as was the requirement for dextran therapy.
Postoperative assessment. All patients were examined postoperatively by the same neurologist (H.A.), who documented any new neurologic deficit or cranial nerve injury. Any new neurologic deficit lasting more than 24 hours was classified as a stroke, and these patients were investigated by means of a computed tomography scan/autopsy, Duplex scanning assessment of the internal carotid artery (ICA), and TCD assessment of the intracranial vessels. The neurologist reassessed all trial patients at 30 days, whereas patients who sustained a perioperative stroke underwent an assessment of the stroke severity with the Oxfordshire Handicap Stroke Score (OHS). 13 The advantage of the OHS over the Rankin score is that it takes into account the disability associated with dysphasia. A minor (nondisabling) stroke scored 0 to 2 on the OHS scale, whereas a disabling stroke scored 3 to 6. All patients underwent a color duplex assessment of the operated artery at 30 days by the same vascular technologist (S.S.) with the ATL Ultramark (Bothel, Wash). Attention was directed toward measuring the maximum diameter of the carotid bulb, excluding carotid occlusion, and diagnosing a stenosis ≥ 70%. At the time of discharge, each patient was asked to complete a visual analog score (range, 1-5) for pain in the groin and neck wounds.
Statistical analysis. Analysis was based on "intention to treat." Any patient randomized to receive a vein patch who then underwent Dacron patching because the vein was inadequate was analyzed on the basis of the original randomization to a vein patch. Similarly, any patient who had already been randomized in the trial and who subsequently required a contralateral CEA received the same type of patch as allocated by the first randomization. The data in this study were not normally distributed; therefore, nonparametric tests were adopted. Continuous variables were analyzed by using the Mann-Whitney U test. Discrete variables were analyzed with the χ 2 or Fisher exact test, as appropriate. A P value less than .05 was assumed to represent statistical significance. patch allocation to which they were randomized during the first CEA. Table I summarizes the changes to treatment after randomization. Five patients (1.8%) underwent reversed saphenous vein bypass grafting procedures because the ICA was either too thin after endarterectomy (n = 2) or had pronounced distal coiling (n = 3), thereby precluding safe patch closure. One patient (0.4%) underwent carotid ligation because the distal ICA lumen was narrow (2-3 mm) and had adherent mural (but not occluding) thrombus extending to the skull base on exploration. MCA flow was indicated by means of TCD to be adequate to tolerate carotid ligation. Finally, three patients (1.1%) randomized to receive a vein patch received a Dacron patch because no suitable vein was found after groin exploration. Table II summarizes the preoperative patient demographics for the two groups, which were well matched for all parameters. In particular, there was no significant difference in presentation, concurrent medical disease, the severity of the carotid disease, the time since the last cerebral event, antiplatelet therapy, and dose of aspirin. Table III details the 30-day perioperative data for patch allocation. There was no significant difference in length of operation, shunt and clamp times, patch length, angioscopy findings, and neck drain losses. Because patients randomized to receive a Dacron patch did not have a groin wound, the overall drain losses were higher for patients in the vein-patch group, and there was, inevitably, a higher incidence of groin wound infections (4.3%) and seromas/hematomas (3.6%) in patients in the vein-patch group. There were no patch infections or ruptures in any patient in this study.
RESULTS

Patient demographics. Three patients underwent bilateral CEAs within the trial, and each received the same
Postoperative outcome. Patch type did not influence the requirement for treating early postoperative hypertension, transfusion requirements, early postoperative reex-ploration for neck hematoma, and time to hospital discharge (Table III) . The median analog score for neck wound pain was 2 (95% CI, 2.4-2.7) for the Dacron-patch group and 2 (95% CI, 2.3-2.5) for the vein-patch group (P = .15). The median analog score for groin-wound pain was 1 (95% CI, 1.0-1.1) for the Dacron-patch group and 2 (95% CI, 2.1-2.4) for the vein-patch group (P < .0001). Table IV summarizes the 30-day morbidity and mortality rate data. The incidence of persisting cranial nerve injury at 30 days (excluding the mandibular branch of the facial nerve) was unrelated to patch type (3.6% for Dacron, 2.9% for vein; P = .78). No patient in either group recovered from anesthesia with a new neurologic deficit. The 30-day death/disabling stroke rate was 1.5% for patients in the Dacron-patch group and 2.9% for patients receiving a vein patch. The death/any stroke rate was 2.2% for patients in the Dacron-patch group and 3.6% for patients in the vein-patch group. If the data are reanalyzed according to which patch type the patients actually received in the trial (ie, excluding vein bypass grafting procedures and correcting for crossovers), the death/any stroke rate was 2.2% in the 133 patients in the Dacron-patch group and 3.7% for the 134 patients in the vein-patch group (P = .72).
All survivors underwent a color duplex scan of the operated ICA at 30 days, and no patient in either group was found to have a carotid occlusion or stenosis > 70%. Four patients (2.9%) who were randomized to the Dacron-patch group had a 30% to 69% stenosis detected at 30 days, as compared with nine patients (6.5%) in the vein-patch group (P = .26). The median carotid bulb diameter at 30 days was 10.8 mm (95% CI, 10.3-10.8) for patients in the Dacron-patch group and 12.0 mm (95% CI, 11.9-12.6) for patients in the vein-patch group (P = .001). Frequency distribution of number of emboli detected in first 3 postoperative hours for patients randomized to receive Dacron patches and vein patches. Note that for high rates of embolization, curves overlap.
the Dacron-patch group had a tendency toward having more emboli detected; however, above the threshold of 50 emboli, the two curves virtually overlapped. More important, the presence of high-rate, sustained embolization and the requirement for dextran therapy was unrelated to patch type. Nine patients in the Dacron-patch group (6.6%) required dextran therapy, as compared with seven patients in the vein-patch group (5.0%; P = .62).
If the data are reanalyzed for the 133 patients who actually received a Dacron patch in the trial, as compared with the 134 who underwent vein patching (ie, excluding bypass grafting procedures and crossovers), the basic data remain unchanged. The median embolus count for patients receiving a Dacron patch was five (interquartile range, 1-17), as compared with three (interquartile range, 0-10.5) for patients receiving a vein patch (P = .027). Seven patients (5.3%) who received a Dacron patch had sustained embolization that required dextran therapy, compared with six patients who received a vein patch (4.4%; P = .78).
The causes of surgery-related strokes/deaths are summarized in Table IV . Five of the eight deaths/ strokes (63%) followed cardiac events or intracranial hemorrhage. The incidence of ipsilateral embolic stroke was 0.7% for the whole series. No stroke in this trial followed postoperative carotid thrombosis, and no patient who was randomized to the vein-patch group sustained an ipsilateral stroke caused by an MCA embolism. However, two patients who were randomized to the Dacron-patch group sustained focal embolic strokes (sustained embolization on TCD, focal carotid territory infarction on computed tomography scan). Severe cardiac failure developed in one of these patients in the immediate postoperative period, and reintubation and inotropic support were required. High rates of embolization were demonstrated by means of TCD, but adequate doses of dextran could not be administered because of the patient's severe cardiac failure. He had a disabling hemiparesis after extubation (OHS 3 at 30 days). The second patient had high rates of embolization in the immediate postoperative period that were abolished with dextran (0 emboli detected at 24 hours). However, an upper-limb monoparesis developed on day 5. Profuse MCA embolization was again revealed by means of TCD, and it was rapidly controlled with dextran. His OHS score at 30 days was 1. When they underwent scanning again at 30 days, neither of these patients had duplex evidence of occlusion or a stenosis > 70%.
DISCUSSION
Meaningful interpretation of this study is dependent on these assumptions: (1) the "high-intensity transients" detected by means of TCD after CEA represent particulate emboli rather than gaseous elements or artifacts; (2) sustained embolization is indicative of an increased risk of thrombus formation within the endarterectomy zone; and (3) emboli diagnosed by means of TCD are clinically relevant.
"High-intensity transients" detected by means of TCD were first reported during CEA in 1986, 14 but there was considerable skepticism about their nature and relevance. Many clinicians assumed that they simply represented artifacts. Subsequent work has now clearly shown that small embolic fragments can be detected by means of TCD and that it is possible to differentiate emboli from artifacts by using consensus criteria 15 or dual-gated ultrasound scanning. 16, 17 Similarly, methods capable of differentiating gaseous from solid elements have demonstrated that emboli detected in the postoperative period are exclusively particulate. 9 A number of studies have reported that emboli detected by means of TCD are associated with an increased risk of adverse outcome. Embolization in patients with an asymptomatic carotid stenosis is associated with an increased risk of transient ischemic attack or stroke, 18 whereas the risk of stroke after acute myocardial infarction is significantly higher in patients with TCD evidence of cerebral embolization. 19 Patients with more than 10 emboli detected during the dissection phase of CEA have a higher incidence of postoperative cognitive impairment 20 and magnetic resonance imaging changes indicative of ischemia, 21 whereas excess intraoperative embolization has been associated with an increased risk of operative stroke. 22 However, the most knowledge is currently derived from studies on embolization in the early postoperative period after CEA. Evidence suggests that although a policy of quality-control assessment and intraoperative monitoring can virtually abolish the incidence of intraoperative stroke (apparent on recovery from anesthesia), the incidence of stroke caused by postoperative thrombosis is unaffected and complicates about 3% of CEAs. 10 At reexploration, these patients usually have friable platelet thrombus adherent to the endarterectomy zone (rather than to the patch), with no evidence of underlying technical error. 8 There is now evidence from three continents that shows that patients destined to sustain a postoperative stroke caused by carotid thrombosis have a preceding 1to 2-hour phase of increasing embolization. [3] [4] [5] [6] [7] Despite the high flow rates within the carotid artery, platelets start to adhere to the endarterectomized surface within minutes of flow restoration 23 and serve as a source of ongoing embolization and thrombus accumulation. In a recent study of 500 patients who underwent CEA, as many as 70% of patients had one or more emboli detected in the early postoperative period, but very high rates of sustained embolization developed in only 5% of patients. 2 Levi et al 5 demonstrated that 60% of patients with high rates of postoperative embolization will sustain a stroke. This is in accordance with our own experience 8 and consistent with published data on the risk of postoperative carotid thrombosis. Embolization in this high-risk subgroup can be abolished with incremental doses of intravenous dextran 40, which prevents progression to carotid thrombosis. 11, 12 Thus, the available evidence suggests that sustained postoperative embolization is a high-risk predictor for progression to carotid thrombosis after CEA and that the rate and magnitude of embolization could be used as an indirect marker of a prothrombotic tendency.
JOURNAL OF VASCULAR SURGERY
The randomized trials to date have shown no systematic evidence that vein patches are safer than prosthetic patches, 1 and the findings of this latest study corroborate this. This study has shown no evidence that the 30-day operative risk is related to patch type. Similarly, patch type had no influence on surgery time, drain losses, the need for reexploration, neck wound pain, cranial nerve injury, and the time of hospital discharge. Patients receiving a vein patch inevitably had a higher incidence of groin wound complications. No patient in this series sustained a vein-patch rupture or prosthetic-patch infection. A metaanalysis of a mix of nonrandomized and randomized trials of vein patching versus synthetic patching concluded that vein was superior with respect to recurrent stenosis and possibly carotid thrombosis. 24 This has not been corroborated by the Cochrane overview of randomized trials. 1 These issues will be addressed in the long-term follow-up of these patients.
Despite the findings of the overview of randomized trials, there remains a perception among surgeons that prosthetic patches are probably more thrombogenic than vein patches. In the past, attempts to evaluate the thrombotic nature of the carotid patch with isotope-labeled platelets have been fraught with difficulty. This study is the first to use the rate/magnitude of embolization as an indirect marker of increased thrombotic potential relative to patch type in a randomized trial. In preparation for this study, we observed three factors that led us to hypothesize that it may, paradoxically, be the patient who is "prothrombotic" rather than the patch. First, patients undergoing reexploration for postoperative stroke tend to have thrombus accumulating on the endarterectomy zone rather than on the patch, usually in the absence of any underlying technical error. 8 Second, it was observed that patients undergoing staged, bilateral CEAs had similar rates of embolization after each procedure. 25 Third, we observed that although aspirin therapy had no influence on the rate of postoperative embolization, the platelets of patients destined to have high rates of postoperative embolization had an increased sensitivity to adenosine diphosphate (ADP) stimulation. 26 The results of this randomized trial have shown that although Dacron patches were associated with a small but significantly higher rate of embolization (median, 5 vs 3), the difference was primarily evident in patients with the lowest rates of postoperative embolization. In clinical practice, such low rates of embolization have never been associated with an increased risk of progressing to thrombotic stroke. The incidence of detecting more than 50 emboli was almost identical for each patch type. More important, the incidence of sustained high-rate embolization requiring dextran therapy was unaffected by patch type (6.6% for Dacron, 5% for vein).
However, two patients who received a Dacron patch sustained ipsilateral embolic strokes despite adjuvant dextran therapy. In one patient, adequate doses of dextran could not be administered because of severe cardiac failure. In the second patient, dextran abolished the initial phase of embolization, but the embolization recurred on day 5. The latter is the only example of delayed reembolization that was encountered in more than 650 patients. No occlusion or severe stenosis developed in either patient at 30 days, suggesting that the embolic phase was transient. These two cases suggest that dextran may not be the perfect therapeutic agent for controlling embolization in all high-risk patients, because there are limitations in the patients in whom it can be used and also in its need to be given intravenously. Alternatives to dextran include Rheopro or S-nitrosoglutathione, 27 but neither have been evaluated in large clinical series. However, to put things in perspective, our policy of selective dextran therapy has been associated with a 0.7% incidence of embolic stroke for the study group as a whole, which is significantly better than our experience before implementing the protocol. 2 Moreover, it has undoubtedly contributed toward a 0% incidence of early postoperative occlusion in 650 patients.
In summary, the findings of this study support the hypothesis that prosthetic patches are as safe as vein patches with regard to their thrombogenicity. Future research must be directed at identifying why a small subgroup of patients who undergo CEA appears to be at such a high risk for the development of high-rate embolization, thereby enabling other therapeutic strategies (eg, the preoperative administration of ADP antagonists) to be considered. This would not only make the surgery even safer, but would clearly remove the need for any postoperative TCD monitoring.
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